HIV-1 virus cycle replication: a review of RNA polymerase II
  transcription, alternative splicing and protein synthesis by Pascual, Miguel Ramos
HIV-1 virus cycle replication: a review of RNA polymerase II transcription, alternative splicing 
and protein synthesis  
Corresponding autor:  Miguel Ramos-Pascual (ramosmi@geneticsvlc.es) 
Affiliation:   Department of Virology and Treatments 
Genetics Vlc – Medical Solutions (Valencia, Spain) 
http://geneticsvlc.es 
Abstract 
HIV virus replication is a time-related process that includes attachment to host cell and fusion, reverse 
transcription, integration on host cell DNA, transcription and splicing, multiple mRNA transport, protein 
synthesis, budding and maturation. Focusing on the core steps, RNA polymerase II transcripts in an early 
stage pre-mRNA containing regulator proteins (i.e nef,tat,rev,vif,vpr,vpu), which are completely spliced by 
the spliceosome complex (0.9kb and 1.8kb) and exported to the ribosome for protein synthesis. These 
splicing and export processes are regulated by tat protein, which binds on Trans-activation response (TAR) 
element, and by rev protein, which binds to the Rev-responsive Element (RRE). As long as these regulators 
are synthesized, splicing is progressively inhibited (from 4.0kb to 9.0kb) and mRNAs are translated into 
structural and enzymatic proteins (env, gag-pol). During this RNAPII scanning and splicing, around 40 
different multi-cystronic mRNA have been produced. 
Long-read sequencing has been applied to the HIV-1 virus genome (type HXB2CG) with the HIV.pro software, 
a fortran 90 code for simulating the virus replication cycle, specially RNAPII transcription, exon/intron splicing 
and ribosome protein synthesis, including the frameshift at gag/pol gene and the ribosome pause at env 
gene.  All HIV-1 virus proteins have been identified as far as other ORFs. As observed, tat/rev protein 
regulators have different length depending on the splicing cleavage site: tat protein varies from 224aa to a 
final state of 72aa, whereas rev protein from 25aa to 27aa, with a maximum of 119aa. Furthermore, several 
ORFs coding for small polypeptides sPEP (less than 10 amino acids) and for other unidentified proteins have 
been localised with unknown functionality.  
This review includes other points in the virus cycle that remain still unclear, as future research lines, such as 
the attachment to other host cells different to CD4 lymphocytes, the reverse-transcription and integration 
of the second RNA strand of the HIV virus, the presence of several cleavage sites for polyadenylation in the 
whole genome, regulation of splicing process, other ribosomal pausing/frameshifting, the antisense protein 
synthesis, docking of gp120/41 glycoproteins into cell-membrane and characterisation of binding site region 
to CD4 lymphocytes co-receptors CCR5/CXCR4, the analysis of the virus cell membrane, including the 
presence of CD4 co-receptors or the protease effect during maturation process. 
The detailed analysis of the HIV virus replication and the characterisation of virus proteomics are important 
for identifying which antigens are presented by macrophages to CD4 cells, for localizing reactive epitopes or 
for creating transfer vectors to develop new HIV vaccines and effective therapies.  
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1. Introduction 
HIV (Human Immunodeficiency virus) is a virion of the family Retroviridiae Lentivirus, which stays in a latent 
state in the host body during several years, developing later, without an effective treatment, the acquired 
immunodeficiency syndrome (AIDS) [1, 2].  
The HIV virus replicates through a special cell of the immunity system, the T-helper lymphocytes cells or CD4. 
After infection and replication, the total number of these cells reduce considerably, increasing the apparition 
of other opportunistic diseases, what is known as the AIDS syndrome [3]. As T-helper CD4 cells are the major 
focus of HIV infection, other cells of the immune system are also attacked by the HIV virus, such as dendritic 
cells, which are one of the first cell to encounter HIV in the mucosal epithelia [4]. 
The HIV virus cycle has been extensively studied and analysed, still focus of current research [5], as far as the 
HIV genomics and proteomics [6]. HIV virus replication is a time-related process that includes host cell fusion, 
reverse transcription, integration on DNA host cell, transcription, pre-mRNA splicing, multiple mRNA 
transport, protein synthesis, budding and maturation. 
Several studies have focused on the transcription process, including the spliceosome complex assembly and 
splicing [7-13]. Protein synthesis and protease enzymatic activity is still under research [14]. Others have 
investigated the geometrical evolution of the capsid during maturation [15,16]. Despite all these advances, 
some features of the virus replication are still unknown, such as the role of some genes during translation or 
the presence of further open reading frames (ORF) encoding polypeptide chains, still not identified [17].  
RNA structure prediction software has been previously developed and classified based on the method 
applied to the genome sequence. These codes analyse the genome nucleotide per nucleotide, comparing 
codons with consensus sequences or repetition sequences [18] The HIV.pro software has been developed for 
simulating the HIV-1 virus cycle replication, focusing in the transcription, splicing and protein synthesis. 
This review includes other points in the virus cycle replication that remain still unclear, such as the 
attachment to other host cells different to CD4 lymphocytes, the reverse-transcription and integration of the 
second RNA strand of the HIV virus, the presence of several cleavage sites for polyadenylation in the whole 
genome, regulation of splicing process, other ribosomal pausing/frameshifting, the antisense and other 
protein synthesis, docking of gp120/41 glycoproteins into cell-membrane and characterisation of binding site 
region to CD4 lymphocytes co-receptors CCR5/CXCR4, the analysis of the virus cell membrane, including the 
presence of CD4 co-receptors or the protease effect during maturation process. 
 
  
2. The HIV retrovirus: structure, genome and virus cycle 
2.1 Structure of the virion 
The HIV virus has a diploid single-stranded RNA genome protected by several envelopes: a spherical lipid 
membrane, a matrix (MA) of protein p17, which support the membrane, a cone-based capsid (CA) of protein 
p24, and a nucleocapsid (NC) of protein p7, binding to the viral RNA. Spacer peptides p2/p1 are protein 
connectors making the nucleocapsid stable. Another protein, p6, is auxiliary in the processes of incorporation 
of the genome into new viruses [14-16]. 
On the external surface of the spherical capsid, it is localised the glycoprotein gp160, which is the 
combination of a protuberance spike (gp120), with several conformation loops (V1 to V5), and a 
transmembrane connector (gp41) [19-20]. Virus membrane is produced through budding of host-cell 
membrane, so can include host-cell connectors in the surface (i.e. MHCII, CCR5…) [53-54] 
Inside all these structures, several enzymes are present, such as reverse-transcriptase (RT), protease (PR) and 
integrase (IN). All retroviruses undergo reverse-transcription of the messenger mRNA into double-stranded 
DNA, which once introduced into the host DNA cell, is transcribed into mRNA segments that produce the new 
proteins of the virus. 
Other viruses, such as the poliovirus that causes paralytic poliomyelitis, have similar structures, enzymes and 
envelopes as the HIV virus [21] 
2.2 Virus genome 
The HIV-1 genome is composed of a duplicated positive-sense single-stranded RNA. Each RNA strand has 
approximately 9700 nucleotides long and encodes all the proteins and enzymes of the virus. The genome is 
poly-adenylated at its 3’-terminus and it contains a long 5’-terminus followed by a short repetition 5’-R 
terminus, which includes the poly(A) tail. Another special characteristic of this genome is a secondary 5’-
terminus after the repetition ltr sequence (see Annex A).  
The genome has several genes classified as: structural (gag/pol/env), regulatory (tat/rev) and accessory 
(nef/vif/vpr and vpu). These genes decode envelope virion proteins, create enzymes, and promote the 
transcription and infection of the virus. Fig. 1 shows the position of the HIV-1 (HXB2) genes in the genome. 
 
Figure 1 – Scheme of the HIV-1 (HXB2) genes and position in the frameshift 
  
2.3 HIV proteins coding sequences (CDS) 
HIV genes superpose each other in three different reading frames [22]. An open reading frame (ORF) is 
defined as any nucleotide sequence starting with an AUG- codon and ending with codon -UAA/UAG/UGA, 
which can be translated into a protein in the ribosome. If a sequence contains several ORF, the mRNA 
fragment is called multi-cystronic.  
HIV virus is polycistronic, that is, messenger RNAs encode multiple polypeptides in a segment. For example, 
the gag-pol or the vpu-env genes produce bicistronic mRNA [23-27] The second (and subsequent) ORF are 
less efficiently translated by the ribosome, unless an IRES (Internal Ribosome Entry Site) is found between 
them [28-30] [61]. Table 1 presents the main genes and a description of the function during the replication. 
Table 1 - Summary of the main genes and characteristics of HIV-1 [31] [47] 
Type Gene Function 
Structural 
gag Envelope of the virion: MA (p17), CA (p24), NC (p7), p2/p1, p6  
Pol Enzymes protease (p10), reverse-transcriptase (p51/p66), R nuclease (p15) and integrase (p31) 
Env Protein gp160 on the virion envelope: Spike glycoprotein (gp120) and transmembrane region (gp41) 
Regulatory 
Tat Promotor of the transcription of viral genome – enhances RNA polymerase II mediated elongation 
Rev Promotor of export of incompletely spliced viral RNAs 
Auxiliary 
Nef Negative effector p24 – promotes downregulation of surface CD4 and MHCI expression, promotes viral infectivity 
Vif Virion infectivity factor p23 – inhibitory effects of host factor (APOBEC3G)  
Vpr Viral protein R – increases viral replication, facilitates infection of macrophages 
Vpu Viral protein U – promotes CD4 degradation and virion release 
Antisense protein Asp Antisense Protein (ASP), citation in [64,65] 
 
2.4 Virus replication cycle 
2.4.1 Introduction 
HIV virus replication is a time-related process that includes attachment to host cell and fusion, reverse 
transcription, integration on host cell DNA, transcription and splicing, multiple mRNA transport, protein 
synthesis, budding and maturation (see figure 2) 
2.4.2 Attachment and fusion 
HIV virus binds preferentially to CD4 lymphocytes, specially to the CD4 receptor in the cell membrane, 
creating a change in the conformation of the gp120 glycoprotein loops and binding to the chemokine co-
receptor CCR5 or co-receptor CXCR4. After this attachment, transmembrane gp41 produces fusion of both 
membranes, releasing provirus into the cytosol [32].  
As HIV virus membrane is formed from CD4 lymphocytes cell membrane, other co-receptors (i.e. CCR5 and 
CXCR4) could be present and used by the virus during the infection process [63]. 
Some other studies have proved binding with other cells of the immune system, as dendritic cells, as 
commented previously [4]. 
 
 
 
 
 
Figure 2 – Scheme of the HIV virus cycle replication (Image generated with BioRender http://app.biorender.io) 
 
2.4.3 Reverse-transcription and integration 
The single-stranded RNA undergoes reverse-transcription by the virus reverse-transcriptase enzyme, 
producing first a cDNA strand with virus RNA as template. Ribonuclease H degrades the union between the 
template RNA and cDNA [33] and later the cDNA is complemented into a dsDNA by the reverse-transcriptase 
[34]. HIV Integrase enzyme binds the copied virus dsDNA into the host cell DNA, specially into active 
transcription units, as the LEDGF/p75 factor [35].  
If the second +ss RNA of the virus is also reverse-transcribed and integrated has not been previously reported. 
Figure 3 presents a model of the HIV reverse-transcription with double +ss RNA and double integration, in 1-
site with directions 5’-3’, 5’-5’ or 3’3’, or in 2 different sites of the host cell. 
 
 
  
Figure 3 – Scheme of a double reverse-transcription and integration during the HIV virus replication cycle, depending 
on different hypotheses: 1-site integration, with three different viral DNA directions and 2-sites integration (Image 
generated with BioRender http://app.biorender.io) 
 
2.4.4 Transcription 
RNA polymerase II of the host cell starts to transcript precursor mRNA. RNAPII interacts with specific 
promoters in the viral DNA, located in the 5’ltr region [36]. The minimal functionality for transcription needs 
the presence of three elements (promoter region): SP1 binding sites, the TATA box and an initiator sequence. 
Another promoter region has been identified in the 3’ltr [37-39] 
Firstly, and during transcription, a 5’cap is added to the pre-mRNA. After capping, there is an elongation 
phase, in which sometimes splicing also occur. After that the segment is released and in a competitive way, 
the 3’ terminus is polyadenylated and the sequence spliced. 
2.4.5 Splicing 
Splicing is the segmentation of the transcribed sequence to a final mRNA, allowing the export of small 
fragments of mRNA out from the nucleus and producing protein isoforms from the same gene. Exons and 
introns are delimited by 5‘ splice donors and 3’ acceptors splicing points [7-13] [62] 
At the beginning of transcription, precursor mRNA is fully spliced into segments of 1.8kb which pass through 
the nucleus membrane and exported to the ribosome. 
The presence of viral regulatory proteins rev and tat increases [40-41], regulating and accelerating the 
complex process of gene expression and mRNA transport from the nucleus to the cytoplasm. Tat protein 
binds with Transactivation Responsive region (TAR), increasing the transcription of pre-mRNA. 
The length and complexity of the mRNA increases from fully spliced to incompletely spliced, as the splicing 
process is inhibited, decreasing the efficiency of spliceosomes. Rev protein interacts with a region on env 
gene, the Rev Responsive Element (RRE), exporting out from the nucleus the mRNA before being completely 
spliced. The RRE element is a ~350 nucleotide region in the vpu/env gene which acts as a scaffold of the rev 
protein. The length of the mRNA segments increases from from 1.8kb to 4.0kb and 9.0kb mRNA lengths. In 
this late phase, the capsid and envelope proteins are translated and rearrange into an immature virion state 
[42]. Figure 4 shows a scheme of the complexity of the splicing process depending of the stage. 
 
Figure 4 – (a) At an early stage, provirus genome undergoes several inefficient splicing, releasing introns D1[A] and D4[A] which 
have the highest spliceosome binding intrinsic strengths [55], with [A] a variable 3’ss and producing 1.8kb mRNA, which encode 
proteins rev/tat and nef,vif,vpr. (b) In an intermediate stage, as rev protein binds with RRE element, 4.0kb mRNA are exported 
before splicing D4[A] and vpu/env protein is translated. (c) At the end, splicing D1[A] is inhibited and the full-length genome 9kb is 
exported out from the nucleus and gag/pol protein translated. 
2.4.6 Translation, protein synthesis and maturation 
Some of the methods that the HIV uses for protein synthesis are frameshifting, ribosome shunting/leaky 
scanning and cap-independent mechanisms though IRES (Internal Ribosome Binding Site) [23-24] [28-30]. 
Other methods are SP-(Stem Pause), producing breakage of the chain during peptide synthesis, as the SP-
stem located between the spacer peptide 1 and gp120 protein in env gene [6]. 
HIV genome includes a programmed (-1) ribosomal frameshift, also known as ‘slippery site’, in the gag-pol 
gene. During ribosome scanning and after this frameshift, reading frame changes to another and start 
translation of pol protein [43-44] This change in the reading frame occurs around 5-10% of the times, 
permitting the development of capsid proteins in a frequency higher than virus enzymes. 
A low frequency of cases, around 5%, the AUG- codon is skipped and translation starts on the second, which 
is significative in multi-cystronic mRNAs. The second (and subsequent) ORF are less efficiently translated by 
the ribosome, unless a IRES (Internal Ribosome Entry Site) is found between them. 
Protease enzyme synthetizes these proteins after proteolysis of the long chain polypeptides released by the 
ribosome [45] Although some studies have reported different cleavages sites in a polypeptide chain for a 
single protease [46], HIV protease has a high sequence specificity for single cleavage points in octapeptide 
regions, for instance in the gag-pol fusion protein.  
After proteolysis, virion is assembled in an immature state, crosses cell membrane (budding) and further 
structural changes into the proteins produce the final virus state (maturation) [56].  
3. HIV.pro software 
3.1 Description 
The software HIV.pro is a Fortran f90 code developed for the analysis and simulation of HIV-1 virus and 
protein synthesis. The software reads as input the virus genome (RNA) from an external file in FASTA format, 
and using a single long-term sequencing method, after reverse-transcription and RNAPII transcription, 
alternative splicing and intron removal, identifies the polypeptide chains in all possible mRNA. Each mRNA 
has been spliced using the donor and acceptor splicers defined in [10] [47]. Figure 5 presents the main screen 
out of the software. 
The software searches for open reading frames (ORF) in the RNA sequence after cleavage and splicing, 
considering the reading frame, that is, separated by a three-multiple number of codons and creates an output 
file for each one of these proteins in FASTA format [48]. The NCBI REFSEQ (Ag 2018) HIV virus sequence has 
been used as input for the HIV.pro software, as commented previously [31] [57-59].  
 
 
Figure 5 – HIV.pro software for simulating HIV virus replication cycle 
 
  
3.2 Transcription and splicing model 
During all splicing process, more than 40 different classes of mRNA are produced with different lengths, from 
approximately 0.9kb (completely spliced) to 9kb (incompletely spliced). These segments have been modelled 
with the 5’ss donor and 3’ss acceptor sites from [10]. Tables 2-3 show the details of these mRNA segments. 
A4* and A7* have several different cleavage sites for the spliceosome complex protein U2 snRNP, suggesting 
unstable cleavage points in some stages of the splicing. 
 
Table 2 – Description of the introns 5’and 3’ donor/acceptor sites [10] 
5’ splice donor (Γ) 3’ splice acceptor (˩) 
D0 1 A0 455 
D1 743 A1 4913 
D2 4962 A2 5390 
D3 5463 A3 5777 
D4 6044 A4* (c/a/b) 5936/5954/5960 
D5 6724 A5 5976 
 
A6 6611 
A7*(7/7a/7b) 8335/8341/8369 
A8 9161 
 
Table 3 – Description of spliced, partially spliced and unspliced multi-cystronic mRNA, the number of splices per segment and the 
characteristics of the introns released 
 
 
3.3 Translation and protein synthesis model 
Ribosome synthesize proteins from messenger RNAs starting scanning from a ribosomal binding site (RBS), 
as the 5’cap site or an IRES (Internal Ribosome Entry Site). The sequence is scanned from 5’ to 3’ direction 
until the first AUG- codon is found. If the first codon is in a weak context, leaky scanning skips this sequence, 
scanning to the next AUG- codon.   
Gag-pol gene contains a programmed ribosomal (-1) frameshift sequence in position [2086], consisting of the 
sequence -UUUUUA- followed by a -UACAA- cap 9 base-pair long stem-loop, which causes the pause during 
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ribosome translation and shifting position in one nucleotide less. This frameshift produces that a single mRNA 
sequence can be translated in two different ways: a gag p55 precursor [790-2292], encoding capsid proteins, 
and with a low frequency a gag-pol fusion protein [790-5096], encoding capsid and HIV enzymes.  
Another -UUUUUA- sequences have been identified in positions [4230] and [6747], corresponding with pol 
and env genes.  However, it has not been previously reported if these frameshifts have been effective. 
There is also a ribosomal SP-stem pause with peptide release in the env gene, before encoding of glycoprotein 
gp120 (see fig. 6) 
Figure 6 – (a) Ribosomal (-1) frameshift in the gag.pol gene. During translation of gag protein, ribosome pauses at the stem-loop, 
shifting around 5-10 % times reading-frame in -1 nucleotide and translating gag-pol protein. (b) Ribosomal Sp-pause in the env 
gene. During translation of env protein, ribosome pauses before the SP-stem loop, releasing the Sp1 signal peptide protein and 
starting the synthesis of gp120 protein. 
3.4 Virus maturation 
Gag-pol protein precursors emigrate to the cell membrane forcing the budding of the virus in an immature 
state. After budding, the protease enzyme proteolyzes the gag-pol protein precursors to form the mature 
state of the virus.  
 
4. Results and discussion 
4.1 Summary 
The software HIV.pro simulates the virus replication cycle, modelling specially the transcription process, 
alternative splicing, ribosomal translation and protein synthesis, and producing several FASTA files with the 
encoded HIV proteins. 
4.2 Splicing 
The HIV.pro has localised the splicing donor sites (5’ss) with highest intrinsic strength, D1 and D4 (fig. 7), with 
a slightly difference of +2 nucleotides in the D4 5’ss reference value [10] Further development is still needed 
to predict how other 5’ss and 3’ss are selected by spliceosome complex proteins, including exonic/intronic 
enhancers and silencers (EES/ESS/IES/ISS) [49,50] [55].  
 Figure 7 – Splicing simulation with HIV.pro software 
 
4.2 Transcription: polyadenylation 
The software HIV.pro has identified several polyadenylation cleavage signal Poly(A) in the whole genome, 
including Poly(A) signals in 5’LTR and 3’LTR [31].  
Polyadenylation signals are characterised by the consensus sequence -AAUAAA-, a -CA- sequence and a U/GU 
rich region. Most of these Poly(A) signals are removed during splicing, within introns. For instance, in the 
early stage of transcription, intron D1A1 removes poly(A) signals 2, 3, 4 and 5, and intron D4A7* removes 
poly(A) signals 6, 7 and 8.   
These Poly(A) signals are localised after a coding region sequence (CDS), suggesting the hypothesis that 
poly(A) signals could regulate also some protein expression. 
If all these poly(A) signals are significative for starting polyadenylation is still unknown, because at the 
moment poly(A) signals observed as polyadenylation initiators are those placed in the 5’ltr and 3’ltr region 
[51]. However, these unidentified poly(A) signals are followed by several CA sequences, instead of a single 
sequence CA. In particular, poly(A) 6 has the highest U/GU rich region (see table 4). 
Table 4 – Description of the Poly(A) signals for the polyadenylation complex and CDS regions in the HIV-1 (HXB2CG) 
CDS i j Poly(A) signal 
-AAUAAA- 
sequence 
position 
N. of CA 
Sequences  
GU rich 
region (%) 
U/GU 
rich 
Region 
(%) 
Comments 
5’LTR U3 1 455   
 Poly(A) 1 527 1 26 39 5’LTR Poly(A) signal 
5’LTR U5 552 633 
 
Removed with intron 
D1A1 
gag /p17 790 1185 
 Poly(A) 2 1600 4 6 31 
gag /p24 1186 1881 
 
gag /p2 1882 1920 
gag /p7 1921 2085 
gag /p1 2086 2133 
 Poly(A) 3 2288 3 10 39 
gag /p6 2134 2292 
 
pol / PR 2253 2549 
 Poly(A) 4 2639 2 6 47 
pol /p51 RT 2550 3869  
 Poly(A) 5 4124 5 8 42 
pol /p66 RT 2550 4229 
 pol / p15 Rnase 
H 
3870 4229 
 Poly(A) 6 4692 3 10 35 
pol /p31 IN 4230 5096 
 
Removed with intron 
D4A7* Vif 5041 5619 
Vpr 5559 5850 
Tat exon 1 5831 6045 
Rev exon 1 5970 6045 
Vpu 6062 6310 
 Poly(A) 7 7290 4 20 54 
 Poly(A) 8 7481 4 12 42 
env /gp120 6315 7757 
 
Asp 7373 7942 
 Poly(A) 9 8070 3 2 39 
env /gp41 7758 8795 
 
 
Tat exon 2 8379 8469 
Rev exon 2 8379 8653 
 Poly(A) 10 9265 4 12 34 
nef 8797 9417   
 Poly(A) 11 9612 1 14 35 3’LTR Poly(A) signal 
 
4.3 Protein synthesis 
The software HIV-1 has localised all HIV-1 proteins (gag/pol, vpu/env, tat, rev, vif, vpr, vpu and nef) and the 
stage in which they were produced (early, intermediate or late transcription). As HIV mRNAs are multi-
cystronic, some proteins are synthesised firstly or in a second place by the ribosome. Table 5 presents the 
HIV-1 proteins, the number of amino acids and the mRNA sequence that encodes them. 
 
Table 5 – Description of the HIV-1 proteins and the mRNA sequence where 
Transcription stage Length Protein Amino acids 
mRNA sequence(a) 
1st protein translated As secondary protein 
Stage (I): 
Early transcription 
0.9kb nef (b) 123 nef1 - 
1.8kb 
Vif 192 vif1 - 
Vpr 78 
vpr1,vpr2,vpr1.7a,vpr2.7a 
vpr1.7b,vpr2.7b 
- 
Tat Variable(c) 
tat1, tat2, tat3, tat4 
tat1.7a,tat2.7a,tat3.7a,tat4.7a 
- 
Rev Variable(d) 
rev1 to rev12 
rev1.7a to rev12.7a 
rev1.7b to rev12.7b 
Vpr1, vpr2 
nef (b) 123 nef2,nef3,nef4 
Vpr1,vpr2 
Rev1 to rev12 
Stage (II): Intermediate 4.0kb 
Vif 192 vif2 - 
Vpr 78 vpr3,vpr4 - 
tat 72 tat5,tat6,tat7,tat8 - 
rev 27 
env2,env3,env4 
env6,env7 
env9,env10,env11,env12 
env14,env15,env16 
vpr3,vpr4 
vpu 82 - Tat5,tat6,tat7,tat8 
env (b) 856 
env1 
env5 
env8 
env13 
env2,env3,env4 
env6,env7 
env9,env10,env11,env12 
env14,env15,env16 
vpr4,vpr3 
nef (b) 123 - vif2 
Stage (III):  
Late transcription 
9.0kb Gag-pol 500 Full length mRNA - 
(a) mRNA sequences defined as Purcell and  Martin (1993) [7] 
(b) Ribosomal leaky scanning 
(c) If mRNA is created with exon 7, protein with 224aa; if exon 7a, with 222aa and with exon 7b, 89. If exon 6 is included, tat has 76aa. 
(d) If mRNA is created with exon 7, protein with 25aa; if exon 7a, with 52aa and with exon 7b, 119. If exon 6 is included, rev has28aa. 
4.3.1 Nef 
Nef1 sequence is the shortest mRNA produced during all the process, encoding only nef protein. Nef protein 
is translated in the early stage of transcription with exon 7, after a ribosomal leaky scanning. Nef length is 
constant during all the process, not influenced by the A7* 3’ss. 
4.3.2 Tat/rev 
Tat and rev proteins are encoded in the virus genome between spliced exons. The AUG- starting codon of tat 
protein is in exon 4 and the end codon in exon 7, whereas rev protein has starting codon in exon 4cab and 
end codon in exon 7ab. As exons 4cab and 7 has variable 3’ss acceptor sites, the released intron and coding 
sequence have different lengths.  
In the case of a completely spliced 1.8kb mRNA, exon 7 produces the longest tat protein, with 224aa and the 
smallest rev, with 25aa, whereas exon 7b produces the opposite, tat with 89aa and rev with 119aa. 
As far as splicing is inhibited, in the case of 4.0kb mRNA, tat and rev reach constant lengths of 72aa and 27aa. 
Exon 7 is determinant in the length of both proteins, tat and rev, whereas exon 4cab is not determinant in 
the length of protein rev. Exon 6 produces tat/rev proteins with constant length, independent of A7 value. 
If exon 6 is included (A6-D5), tat protein has a length of 76aa and rev of 28aa. This expression of tat/rev 
protein has been previously described in some studies as tev protein [52]. 
As these proteins are absent or in a low frequency in most of the HIV analysis, splicing happens inefficiently 
in early stages, until the synthesis of tat/rev proteins are stable. 
Annexes B and C describes the tat and rev splicing and the FASTA files of the proteins. 
4.3.3 Vpu 
Vpu is translated as a secondary protein with tat5 to tat8 mRNA segments. Although vpu and env genes share 
a common nucleotide region, both proteins are independently translated in different mRNA. 
4.3.4 Env 
A ribosome shunting regulates translation of env protein, produced by the sequence -AUG-UAA-. After this 
shunting, ribosome continues scanning env gene until founding an Sp- stem-loop, placed at the beginning of 
gp120 glycoprotein, making a pause long enough to disrupt the polypeptide synthesis, releasing signal 
peptide 1 (Sp1) protein and continuing translating gp120 and gp41 glycoprotein (gp160) [6]. After translation, 
glycoprotein gp160 binds to the cell membrane. Other regions are encoded in env gene, as the antisense 
protein (asp), although there is still no evidence of being translated during the HIV virus cycle. Figure 8 and 
table 6 presents a scheme of the characteristic regions of env gene. 
Several studies have reported the placement of the binding site of the gp120 to CD4 cells in some region 
between the conformation loops, although it is still unclear. 
 
 
Figure 8 – Scheme of env gene, starting with a ribosome shunting, SP-stem pause and translation of gp120/gp41 proteins  
 
 
Table 6 - Description of env proteins [31] 
  i j Description 
Sp1 - 6225 6314 Signal peptide 1 before stem loop 
gp120 
[6315-7757] 
V1 6615 6692 V1 loop 
V2 6696 6812 V2 loop 
V3 7110 7217 V3 loop 
V4 7377 7478 V4 loop 
VBS-CD4 7479 7601 Binding site CD4 (a) 
V5 7602 7634 V5 loop 
gp120-gp41 
RRE 7710 8061 Rev responsive element (RRE), binding site of rev protein  
Asp 7942 8795 Antisense protein 
gp41 
[7758-8795] 
Gp41 TMD 8277 8336 Transmembrane domain of gp41 glycoprotein 
(a) Other studies suggest HIV binding site to CD4 receptor between V2/V3 [63] 
4.3.5 Gag-pol proteins 
At the end of the transcription process, spliceosome activity is inhibited and full-length 9.0kb mRNA are 
exported to the ribosome for translation, encoding gag-pol protein. As commented, gag-pol can be translated 
into two different polypeptide chains with a different probability, due to the ribosomal frameshift (table 7). 
These polypeptides chains reorganise and bind to the cell membrane to conform an immature provirus which 
buds out of the cell. HIV virus maturation is still unknown, being protease enzyme decisive in this process. 
 
Table 7 - Description of gag-pol protein: precursor p55 and gag-pol fusion protein p160 [47] 
P(%) Polypeptide RF i j Aa Proteins Function Description 
90-95 Gag precursor 
(p55) 
+1 790 1185 132 p17 (MA) Structural Spherical matrix to support lipid membrane 
1186 1881 232 P24 (CA) Capsid 
1882 1920 13 p2 Connector Spacer peptide 1 
1921 2085 55 p7 (NC) Structural Nucleocapsid 
2086 2133 16 p1 Connector Spacer peptide 2 
2134 2292 53 p6 Assembly Facilitates ESCRT-dependent budding and allows 
incorporation of vpr into virus 
5-10 Gag-pol fusion 
(p160)  
+1 790 2085 432 P17/p24/p2/p7 Structural Gag proteins 
+3 2085 2252 56 TFP  Trans-frame fusion protein 
2253 2549 99 PR/p10 Enzymes Protease 
2550 3869 440 RT/p51 Reverse transcriptase 
2550 4229 560 RT/p66 Reverse transcriptase 
3870 4229 120 Rnase H / p15 Ribonuclease H 
4230 5096 289 IN/p31 Integrase 
 
4.3.6 Other ORF encoding proteins 
A total number of 171 open reading frames (ORF) has been recognised in the whole genome, including the 
HIV-1 proteins previously described. 
Some of these ORF encode proteins with a small number of amino acids that undergo real translation, that 
is, short ORF-encoded polypeptides (sEPs), being unclear if they are significative during the virus replication 
process. Other ORF remain without translation because the starting codon is in a reading frameshift not 
scanned by the ribosome. There are still some proteins that could be translated and remain unidentified, 
because they are degraded during the replication process or because as being the second or third ORF in a 
mRNA translation are produced in a low frequency. Table 8 summarises all these proteins. 
Table 8 - Description of ORF with unidentified proteins in the 1.8kb, 4.0kb and 9.0kb mRNA 
 mRNA 
Start 
codon 
End 
codon 
Aa Protein Comments 
1.8kb 
Nef1,nef2 
Rev1 to rev12 
9313 9418 34 MDDPEREVLEWRFDSRLAFHHVARELHPEYFKNCX After nef protein 
Vpr1, vpr2 
Tat 1 to tat4 
8832 8868 11 MAYCKGKNETSX  
9216 9243 8 MVLQASTSX Also in [131-158] 
4.0kb 
Vif2 
5641 5686 14 MKLLDIFLGFGSMAX  
5698 5740 13 MKLMGILGQEWKPX  
6343 6478 44 MGYLCGRKQPPLYFVHQMLKHMIQRYIMFGPHMPVYPQTPTHKKX  
6925 6988 20 MEQDHVQMSAQYNVHMELGQX  
8056 8149 30 MLVGVINLWNRFGITRPGWSGTEKLTITQAX  
9313 9418 34 MDDPEREVLEWRFDSRLAFHHVARELHPEYFKNCX As found in 1.8kb mRNA 
Vpr3,vpr4 
Env1 to env16 
8832 8868 11 MAYCKGKNETSX As found in 1.8kb mRNA 
9216 9243 8 MVLQASTSX As found in 1.8kb mRNA 
Tat5 to tat8 
6557 6608 16 MGSKPKAMCKINPTLCX  
6938 6980 13 MYKCQHSTMYTWNX  
7475 7556 26 MQNKTNYKHVAESRKSNVCPSHQWTNX  
7556 7604 15 MFIKYYRAAINKRWWX  
8915 8972 18 MEQSQVAIQQLPMLLVPGX  
9308 9341 10 MGWMTRREKCX  
9.0kb Gag/pol 1251 1409 52 MGKSSRREGFQPRSDTHVFSIIRRSHPTRFKHHAKHSGGTSSSHANVKRDHQX Reading frame +3 
5. Conclusions 
The software HIV.pro identifies with high accurateness the location and the amino acid composition of the 
proteins in the HIV1(HXB2) genome, producing the FASTA files for further analysis. All HIV-1 proteins have 
been localised in the genome sequence, making special attention to the tat/rev proteins. In this case, it has 
been observed that the length of these proteins depends on the splicing process, especially on the 3’ss 
acceptor site A7, where the U2 snRNP spliceosome protein binds during splicing. Furthermore, other ORF 
that could be translated into proteins have been identified. 
The software has identified other features, as ribosomal frameshifting sequences and cleavage signals for 
polyadenylation, needing special focus and analysis.  
Although this type of software has been extensively developed, with different kind of features and analyses, 
as for identifying secondary structures or enhancers/silencers sequences (ESE/ESS/ISS), it can be applied to 
any type of genome, allowing further implementations, such as splicing prediction or mutations. Other HIV-
1 genome sequences and subtypes will be analysed in future studies. 
The detailed analysis of the HIV virus replication and the characterisation of virus proteomics are important 
for identifying which antigens are presented by macrophages to CD4 cells, for localizing reactive epitopes or 
for creating transfer vectors to develop new HIV vaccines and effective therapies, where intensive research 
is still needed. 
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Annex A. HIV-1 genome sequence: type HXB2CG 
The NCBI (National Center for Biotechnology Information) has published the last version of the HIV-1 
complete genome (Aug-2018). This sequence is based on a compendium of isolated and/or fractional 
genomes, aligned to an initial alignment sequence [31] [50] 
The NCBI REFSEQ is a reference genome sequence for the retrovirus HIV-1 subtype (HXB2CG), last version 
NC_001802.1 from Aug-2018. The subtype HXB2 is a clone from the French isolate LAI (formerly LAV-BRU) 
[58]. The sequence includes a total of 9181 nucleotides, arranged mainly in structural, regulatory and 
auxiliary genes. The sequence has been modified including the regions 5’LTR u5 (454bp) and 3‘LTR u5 (84bp), 
from version K03455.1 (2002), for a total length of 9719 nucleotides. 
Table A1 and figure A1 shows a detailed description of the HIV-1 virus 5’ltr and 3’ltr. 
Table A1 – Regulatory elements in the untranslated regions 5’ltr and 3’ltr 
 5’LTR 3’LTR Nucleotide sequence 
LTR U3 [1:455] [9086:9540] - 
TCF-1 alpha  [315:329]                  [9400:9414] uacuucaagaacugc 
NF 
NF-k-B-II [350:359]                  [9435:9444] gggacuuucc 
NF-k-B-I  [364:373]                  [9449:9458] gggacuuucc 
Sp1 
Sp1-III [375:386]                  [9462:9471] gggaggcguggc 
Sp1-II [388:397]                  [9473:9482] ugggcgggac 
Sp1-I [398:408]                  [9483:9493] uggggaguggc 
TATA Box      [427:431]                  [9512:9516] uauaa 
TAR element   [453:513]   [9538:9599] ugggucucucugguuagaccagaucugagccugggagcucucuggcuaacuagggaaccca 
Poly(A) signal [527-532] [9612:9617] aauaaa 
Figure A1 – (a) Description of the main elements of the 5’ LTR promoter region of the RNAPII and (b) 3’ LTR of the HIV-1 genome. As 
observed, both regions include repetitive elements, as the transcription factor NF, Sp1 and TATA box [60]. 
Annex B. Splicing of tat and rev HIV-1 proteins 
 
 
Figure B1 – Splicing of the tat and rev genes: (a) tat protein is formed with a fragment of exon 4 and another from exon 7, 7a or 7b, 
which has a variable length, depending on the 3’ splicing acceptor site A7. Furthermore, in the case of exon 7b, there is a change in 
the reading frame between exons, reducing considerably tat length. Another case, if exon 6 is present, tat length is constant (b) Rev 
protein is formed with a fragment of exon 4c, 4a or 4b and another from exon 7, 7a or 7b. Although 3’ss A4 is variable, is not 
determinant for rev length. If exon 6 is present, rev length is constant  
Annex C. FASTA files 
 
Figure C1 – FASTA file for tat proteins: 1.8kb and 4.0kb mRNAs (not expressed at 9.0kb) 
Figure C2 – FASTA files for rev proteins: 1.8kb and 4.0kb mRNAs (not expressed at 9.0kb) 
 
